Development of a Sensitive Anti-Human CCR9 Monoclonal Antibody (CMab-11) by N-Terminal Peptide Immunization.

The C-C chemokine receptor 9 (CCR9) belongs to the G-protein-coupled receptor superfamily, and is highly expressed on the T cells and intestinal cells. CCR9 regulates various immune responses by binding to the C-C chemokine ligand, CCL25, and is involved in inflammatory diseases and tumors. Therefore, the development of sensitive monoclonal antibodies (mAbs) for CCR9 is necessary for treatment and diagnosis. In this study, we established a specific anti-human CCR9 (hCCR9) mAb; CMab-11 (mouse IgG, kappa), using the synthetic peptide immunization method. CMab-11 reacted with hCCR9-overexpressed Chinese hamster ovary-K1 (CHO/hCCR9) and hCCR9-endogenously expressed MOLT-4 (human T-lymphoblastic leukemia) cells in flow cytometry. The dissociation constant () of CMab-11 for CHO/hCCR9 and MOLT-4 cells were determined to be 1.2 × 10 M and 4.9 × 10 M, respectively, indicating that CMab-11 possesses a high affinity for both exogenously and endogenously hCCR9-expressing cells. Furthermore, CMab-11 clearly detected hCCR9 protein in CHO/hCCR9 cells using western blot analysis. In summary, CMab-11 can be a useful tool for analyzing hCCR9-related biological responses.